Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
Ofertas de empleo y Agenda »Ofertas de empleo grupos RTICC
 
Ofertas de Empleo
Position of Scientist - P4 - IARC Section of Cancer Surveillance (CSU) - Vacancy Notice N° IARC/16/FT342

Application Deadline: 01November 2016

Contract type: Fixed-term Appointment.

Duration of contract: 2 years, renewable.

Duty Station: Lyons, France.

Organization unit: IARC Section of Cancer Surveillance (CSU).

Education:
Essential: Medical Degree or PhD in epidemiology, medical statistics or a related field.
Desirable: First degree in relevant scientific subject or mathematics/statistics.

More information: Objectives of the Programme, Description of duties, Skills, Experience, Languages, Annual salary, etc. in pdf enclosed.

Documentos relacionados:
Reuniones RTICC
Congresos
Otras reuniones científicas
Ofertas de empleo
Becas
Documentos RTICC
Enlaces de interés
Avisos
Noticias
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
21/10/2016 | Reuniones RTICC
29/09/2016 | Becas
Publicaciones
RD12/0036/0012
Unveiling changes in the landscape of patient populations in cancer early drug development.
Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J
Oncotarget  2017.  8.  14158-14172.  PMID: 27835915. 
RD12/0036/0012
The expanding role of immunotherapy.
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J
Cancer Treat Rev  2017.  74-86.  PMID: 28231560. 
RD12/0036/0012
The consensus molecular subtypes of colorectal cancer.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S
Nat Med  2015.  11.  1350-6.  PMID: 26457759. 
RD12/0036/0012
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J
Ann Oncol  2016.  11.  2082-2090.  PMID: 27573561. 
RD12/0036/0012
Single-cell transcriptome conservation in cryopreserved cells and tissues.
Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H
Genome Biol  2017.  1.  45.  PMID: 28249587. 
RD12/0036/0012
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N
Carcinogenesis  2016.  9.  852-7.  PMID: 27381831. 
RD12/0036/0012
SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL
Clin Transl Oncol  2016.  12.  1172-1178.  PMID: 27896637. 
RD12/0036/0012
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  9.  e13.  PMID: 27657342. 
RD12/0036/0012
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  2.  188-94.  PMID: 27351217. 
RD12/0036/0012
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O
Target Oncol  2017.  1.  19-35.  PMID: 27844272. 
ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
  
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
  
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS